MannKind | MNKD - Current Assets


MannKind reported $358.84M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Adma Biologics USD 402.66M 3.1M Sep/2025
BioCryst Pharmaceuticals USD 355.68M 42.78M Sep/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Halozyme Therapeutics USD 825.21M 503.54M Dec/2025
Insmed USD 1.79B 137.6M Dec/2025
Karyopharm Therapeutics USD 89.75M 8.12M Sep/2025
MacroGenics USD 232.09M 27.15M Sep/2025
MannKind USD 358.84M 79.81M Sep/2025
Merck USD 47.56B 10.49B Sep/2025
Minerva Neurosciences USD 13.02M 2.53M Sep/2025
Novavax USD 974.59M 55.08M Sep/2025
Novo Nordisk DKK 25.71B 148.69B Jun/2025
Pfizer USD 46.92B 3.22B Sep/2025
Sanofi EUR 30.95B 3.09B Dec/2025
Xencor USD 518.44M 5.29M Sep/2025